HYPERION DEFI INC (HYPD)
NASDAQHealth CareAsset Management - CryptocurrencySnapshot 2026-09-04
$3.300.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareAsset Management - CryptocurrencySnapshot 2026-09-04
QuarterlyIQ Insights · HYPD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue scaling DeFi operating businesses to increase Adjusted Gross Profit and expand revenue streams.
Stated as a priority in 2 of last 2 quarters. Adjusted Gross Profit increased 162% from $0.4 million in 2025-Q3 to $1.15 million in 2026-Q2, reflecting growth in DeFi operating businesses. Management is delivering on this priority with strong sequential growth.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We have launched multiple scalable businesses and built new products on Hyperliquid, growing Adjusted Gross Profit 162% from $0.4M in Q3'25 to $1.15M in Q2'26.”
“We are pleased to report continued scaling of our DeFi operating businesses, accretive balance sheet growth, and prudent cost management.”
Increase deployment of HYPE tokens in various DeFi activities including staking, validator commissions, yield enhancement, and monetization.
Stated as a priority in 2 of last 2 quarters. Gross HYPE Tokens increased from 1.94 million in 2026-Q1 to 2.04 million in 2026-Q2, with 1 million tokens redeployed to new DeFi markets. Management is delivering on expanding HYPE token deployment across business lines.
“1 Million HYPE Tokens Redeployed to Support HIP-3 & HIP-4 Markets Since June 2026 Sale of Remaining Legacy Life Sciences IP.”
“HYPE Treasury grew to over 2.00 million tokens as of May 11, 2026, with multiple deployment strategies generating ~3.1x base staking income.”
Continue cost discipline by lowering operating expenses and completing exit from legacy biotech operations.
Stated as a priority in 2 of last 2 quarters. Operating Expenses Excluding Stock-Based Compensation declined 46% from $4.3 million in 2025-Q3 to $2.3 million in 2026-Q2, with legacy biotech segment fully wound down by June 30, 2026. Management is delivering on cost reduction and segment exit.
“Operating Expenses Excluding Stock-Based Compensation declined 46% from $4.3 million in Q3'25 to $2.3 million in Q2'26.”
“We expect Operating Expenses Excluding Stock-Based Compensation to decline below $3.0 million quarterly run-rate beginning in Q2'26 driven by exit of legacy biotech operations.”
Develop and grow HAUS agreements with partners to deploy HYPE tokens and generate revenue on Hyperliquid.
Stated as a priority in 2 of last 2 quarters. Management announced multiple HAUS agreements deploying 1 million HYPE tokens and growing trading volumes on Silhouette platform. The trajectory shows active partnership expansion and deployment.
“Announced HAUS agreements with Skew and Entropy deploying 1 million HYPE tokens; Silhouette completed migration with volumes over $40 million.”
“Entered HAUS agreement with Silhouette providing reduced trading fees and revenue share; building pipeline of prospective HAUS clients.”
Improve cash flow through cost control and business growth to reach positive Adjusted Net Operating Cash Flow by year-end 2026.
Stated as a priority in 2 of last 2 quarters. Adjusted Net Operating Cash Flow improved from ($2.8 million) in 2025-Q3 to ($2.1 million) in 2026-Q2, with management anticipating positive cash flow by end of 2026. The trajectory shows progress but cash flow remains negative as of latest quarter.
“Adjusted Net Operating Cash Flow improved to ($2.1 million) in Q2'26 from ($2.8 million) in Q3'25; anticipate positive cash flow by end of 2026.”
“We continue to anticipate achieving break-even cash flows by the end of the year.”
Over the trailing year it converted 1.84x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
37 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.